A group of medical experts reviewed how to identify and manage patients with high-risk prostate cancer recurrence. This occurs when prostate-specific antigen (PSA) levels rise again after initial treatment. The experts focused on patients who have experienced this biochemical recurrence following their primary therapy.
The panel reached agreement on several important topics. They agreed that early detection of high-risk recurrence is crucial, and that patients should be carefully assessed to determine their risk level. They also agreed on the potential role of certain medications called androgen receptor signaling pathway inhibitors (ARPIs) and androgen deprivation therapies (ADT) in early management.
However, the experts did not agree on everything. They lacked consensus on the optimal timing for starting interventions and on strategies for allocating healthcare resources. This review is based on expert opinions and discussion, not on new patient data or clinical trials.
Readers should understand that this represents a summary of current expert thinking, not a proven treatment plan. More research is needed to create better prediction models and to determine the most effective timing for treatment. Patients should discuss their individual situation with their healthcare team.